Ali Etemadi

Ali Etemadi

Auto-generated profile, based on publicly available information

Ali Etemadi

Division of Nephrology, Department of Medicine, Stanford University, Stanford, California

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Thyroid®
Verified
Journal Article
Closed access
AAAtieh Amouzegar
Atieh Amouzegar
MBMahmood Bakhtiyari
Mahmood Bakhtiyari
MMMohammad Ali Mansournia
Mohammad Ali Mansournia
AEAli Etemadi
Ali Etemadi
LMLadan Mehran
Ladan Mehran
FAFereidoun Azizi
Fereidoun Azizi
Background: Current guidelines used for establishing reference intervals for thyroid peroxidase antibodies (TPOAb), recommended by the National Academy of Clinical Biochemistry (NACB), have been a matter of controversy. In the present study, we determined TPOAb reference intervals for different age and sex groups, and the TPOAb cut-off points for subclinical and overt hypothyroidism in an iodine sufficient population Methods: This cross sectional study was conducted within the framework of the prospective Tehran Thyroid Study (TTS), in which 4174 healthy euthyroid individuals were followed for 10 years. Thyroid function tests and TPOAb were assessed. Results: Mean ± SD age of participants was 39.3 ± 15.2 years. Estimated reference intervals for TPOAb corresponding to the 2.5th and 97.5th percentiles were 1.5-32.8 and 2.1-35 IU/mL in males and females respectively. There were no significant variations in the different age groups in either sex. The optimal cut-off points for TPOAb were 18.38 and 14.77 IU/mL for predicting clinical and subclinical hypothyroidism, respectively. Conclusions: This study establishes the reference intervals and the optimal cut-off points for TPOAb in an iodine sufficient population.

14 February 2020 in Thyroid®
Verified
Journal Article
Closed access
AEAli Etemadi
Ali Etemadi
AAAtieh Amouzegar
Atieh Amouzegar
LMLadan Mehran
Ladan Mehran
MTMaryam Tohidi
Maryam Tohidi
FAFereidoun Azizi
Fereidoun Azizi
HDHossein Delshad
Hossein Delshad
Background: Thyroid disorders such as subclinical hypothyroidism and isolated maternal hypothyroxinemia are understudied in pregnant women, despite their possible adverse effects on the health of mother and child. Also, the role of iodine deficiency in developing such disorders has not yet been fully understood. Methods: The present national population-based cross-sectional study was conducted on 1080 randomly recruited pregnant women, aged 20–40 from 12 provinces of Iran from 2013 to 2014. Serum concentrations of thyrotropin, T4, thyroid peroxidase antibody (TPOAb), and triiodothyronine (T3) resin uptake values were measured in fasting blood samples, and urinary iodine concentration (UIC) was measured in three separate urine samples. Multinomial logistic regression was run to analyze the possible risk factors regarding thyroid disorders. To clarify the role of iodine in thyroid status specifically, the determinants of UIC and its correlations with thyroid function tests were investigated independently and through subgroup analysis. Results: Isolated hypothyroxinemia was the most common thyroid disorder (9.9%), followed by subclinical hypothyroidism (8%). In comparison to euthyroid pregnant women, isolated hypothyroxinemia was more likely in pregnant women older than 30 years (odds ratio [OR] = 1.6), in the second and the third trimesters (OR = 2.62 and 2.12 respectively), with history of multiparity (OR = 1.72), residing in rural areas (OR = 1.57) and in the capital province of the country (OR = 3.3). Subclinical hypothyroidism was more likely in TPOAb positive pregnant women (OR = 2.56). All the mentioned ORs were statistically significant ( p < 0.05). The UIC did not correlate significantly with any of the thyroid function tests in the study population. Subgroup analysis showed a significant correlation between UIC and T4 in pregnant women with subclinical hypothyroidism ( p < 0.05). Conclusion: Isolated maternal hypothyroxinemia was the most prevalent thyroid disorder in Iranian pregnant women and its associated risk factors were identified. Although the calculated prevalence of thyroid disorders was expected in a moderately iodine deficient setting, no correlations between UICs and thyroid function tests were found at the individual level. The contribution of iodine deficiency to thyroid condition for each pregnant woman may be more evident in pregnant women with certain thyroid disorders or those with long-term iodine deficiency.

7 February 2023 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Closed access
PDF file
AEAli Etemadi
Ali Etemadi
PDParviz Dabaghi
Parviz Dabaghi
YHYasaman Hosseini
Yasaman Hosseini
MGMehrzad Gholampourdehaki
Mehrzad Gholampourdehaki
SSSogand Solouki
Sogand Solouki
RERadina Eshtiaghi
Radina Eshtiaghi

20 May 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AEAli Etemadi
Ali Etemadi
SLSai Liu
Sai Liu
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
MMMaria Montez-Rath
Maria Montez-Rath
TCTara I. Chang
Tara I. Chang
Key Points: Many major adverse cardiovascular events happen within the first 6 months after hemodialysis initiation. Using nondialyzable β -blockers at hemodialysis initiation was associated with fewer cardiovascular events than dialyzable β -blockers. Background: How β -blocker dialyzability affects cardiovascular outcomes in patients receiving hemodialysis remains unclear. Previous observational studies show conflicting results, and conducting clinical trials in this population has proven challenging. This uncertainty has contributed to substantial variation in β -blocker prescribing patterns across regions and clinicians. Methods: Using data from the United States Renal Data System, we identified patients receiving β -blockers on the day of starting hemodialysis and classified them into nondialyzable and dialyzable exposure groups. Geographical variations in nondialyzable and dialyzable β -blocker prescription rates across neighboring regions in each state were leveraged as an instrumental variable. The treatment effect of nondialyzable versus dialyzable β -blockers on major adverse cardiovascular events (MACE) at 6 months, 1 year, and 3 years was evaluated using instrumental variable g -estimation methods for survival outcomes. MACE comprised myocardial infarction, stroke, and all-cause mortality. Results: The cohort of 40,313 participants from 41 US states experienced 25,720 MACE over the 3-year follow-up period (median years [interquartile range], 1.4 [0.4–3.0]), with more than 42% occurring during the first 6 months after hemodialysis initiation. The instrumental variable met all statistical assumptions. Nondialyzable β -blockers were associated with significantly lower risk of MACE at all three follow-up time points compared with dialyzable β -blockers (hazard ratios [95% confidence intervals], 0.82 [0.74 to 0.90], 0.85 [0.79 to 0.92], and 0.90 [0.85 to 0.96], respectively). Similar patterns were observed for each separate component of MACE. Conclusions: The use of nondialyzable β -blockers compared with dialyzable β -blockers was associated with a lower risk of MACE during all time points, including the early, high-risk period in the 6 months following hemodialysis initiation.

1 December 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
JBJehan Z. Bahrainwala
Jehan Z. Bahrainwala
AEAli Etemadi
Ali Etemadi
TCTara I. Chang
Tara I. Chang
Kidney denervation has emerged as an interventional treatment for the ever-increasing prevalence of uncontrolled hypertension that recently garnered Unites States Food and Drug Administration approval. Kidney denervation is a minimally invasive catheter-based procedure that ablates the sympathetic nerves around the kidney arteries using a variety of modalities. Clinical trial data have generally demonstrated that kidney denervation is a safe procedure, but efficacy data are mixed. In addition, important populations were excluded from these trials, including patients with advanced CKD and kidney transplants. Currently, it is still unclear which patients with hypertension will have an appropriate therapeutic effect after undergoing kidney denervation, and there is no available biomarker to assist in predicting a patient's blood pressure response after kidney denervation. When considering when to offer kidney denervation, patients should ideally be evaluated by a multidisciplinary team with the proper expertise to evaluate the appropriateness of the referral and discuss the risks and benefits to allow for shared decision-making. Ongoing and future studies will help to address current unanswered questions that remain about longer-term safety and efficacy of kidney denervation, particularly in populations poorly represented by current trials. Kidney denervation can be an important therapy that can be used to complement antihypertensive medications and lifestyle changes to improve hypertension control.

2 June 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
TCTara I. Chang
Tara I. Chang
GPGomathy Parvathinathan
Gomathy Parvathinathan
SLSai Liu
Sai Liu
JLJun Young Lee
Jun Young Lee
AEAli Etemadi
Ali Etemadi
MSMargaret R. Stedman
Margaret R. Stedman
Background: The risk–benefit trade‐offs after lower‐extremity revascularization among older patients with chronic kidney disease remain unclear. We compared how surgical versus endovascular lower‐extremity revascularization associates with clinical outcomes that may be valued differently by patients. Methods: We selected adults aged ≥66 years with chronic kidney disease who underwent lower‐extremity revascularization from January 1, 2008, to December 31, 2017, with ≥12 months Medicare Parts A and B before the procedure. The primary outcome was days at home at 30, 180, and 365 days after revascularization. The secondary outcome was major adverse limb events (ie, lower‐extremity revascularization or major amputation). We report outcomes as the difference in survived days at home and days lost due to major adverse limb events by restricted mean time lost. Results: Among 87 446 patients, 15.3% underwent surgical and 84.7% underwent endovascular revascularization. Surgical revascularization was associated with fewer days at home at 30 days (difference, −8.4 [95% CI, −8.6 to −8.2]), 180 days (difference, −21.2 [95% CI, −22.1 to −20.4]) and 365 days (difference, −31.9 [95% CI, −33.5 to −30.6]) compared with endovascular. Surgical revascularization was associated with fewer days lost to major adverse limb events at 180 days (difference, −6.9 [95% CI, −7.6 to −5.8]) and at 365 days (difference, −17.3 [95% CI, −19.3 to −14.7]). Conclusions: In this study of older patients with chronic kidney disease, surgical lower‐extremity revascularization was associated with fewer survived days at home, but also with fewer days lost to major adverse limb events compared with an endovascular approach. Considering different risk–benefit profiles when planning for lower‐extremity revascularization is essential to facilitate shared decision making.